Publication Date
1-1-2022
Journal
Frontiers in Immunology
DOI
10.3389/fimmu.2022.1049908
PMID
36726990
PMCID
PMC9885262
PubMedCentral® Posted Date
1-13-2023
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
Humans, Amoxicillin, Anti-Bacterial Agents, Clarithromycin, Helicobacter Infections, Helicobacter pylori, Prospective Studies, Proton Pump Inhibitors
Abstract
BACKGROUND AND AIM: We previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for
METHODS: This was a single center, prospective, open-labeled, randomized non-inferiority clinical study conducted in China. Treatment naïve
RESULTS: A total of 154 patients were assessed and 110 subjects were randomized. The eradication rate of VPZ with b.i.d. amoxicillin or t.i.d. amoxicillin for 14 days was 89.1% and 87.3% by intention-to-treat analysis, respectively, and 94.1% and 95.9% by per-protocol analysis, respectively. The eradication rate and incidence of adverse events were not different between the two groups.
CONCLUSION: VPZ with b.i.d. or t.i.d. amoxicillin for 14 days provides satisfactory efficacy as a first-line treatment for